Literature DB >> 11268020

The spread of transgene expression at the site of gene construct injection.

A J O'Hara1, J M Howell, R H Taplin, S Fletcher, F Lloyd, B Kakulas, H Lochmüller, G Karpati.   

Abstract

Seven 2-day-old golden retriever pups were given focal intramuscular injections of a first generation adenovirus-dystrophin minigene construct and adenovirus-beta-galactosidase construct as a 2:1 mixture into the left anterior tibial muscle. The spread of transgene expression within the anterior tibial muscle was compared with the spread of methylene blue dye after identical injection into the contralateral muscle. Transgene expression 5-7 days after intramuscular injection was shown to extend between 5.8 and 11.6 mm along the biopsied muscle length (range of biopsy lengths 11.1-12.2 mm). The level of transgene expression at 2-2.5-mm intervals from the site of injection was significantly related to the distance from the site of injection (dystrophin, P = 0.009; beta-galactosidase, P = 0.015). The spread of methylene blue dye within the anterior tibial muscle < or =24 h after identical intramuscular injection demonstrated a similar pattern to the transgene expression, with dye staining measured between 5.5 and 8.5 mm along the muscle sample length (range of biopsy lengths 5.6-15.6 mm). The greatest transgene expression and dye staining was measured 2-2.5 mm proximal to the site of injection with a maximum of 23% of muscle fibers expressing the dystrophin transgene, 95.2% expressing the beta-galactosidase transgene, and 98% of the tissue section stained with methylene blue dye. These results suggest transgene expression after focal intramuscular injection is relatively localized around the site of injection. Further research is required to develop techniques that will provide transgene expression throughout the length and breadth of a muscle. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11268020     DOI: 10.1002/mus.1031

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

Review 1.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

2.  Tissue-specific characteristics of in vivo electric gene: transfer by tissue and intravenous injection of plasmid DNA.

Authors:  Oranuch Thanaketpaisarn; Makiya Nishikawa; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

3.  Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model.

Authors:  S R Bacman; S L Williams; D Hernandez; C T Moraes
Journal:  Gene Ther       Date:  2007-06-28       Impact factor: 5.250

Review 4.  Gene doping: the hype and the reality.

Authors:  D J Wells
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 5.  Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

Review 6.  Duchenne muscular dystrophy gene therapy in the canine model.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-24       Impact factor: 5.032

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.